Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty Black men diagnosed as schizophrenic and admitted to Ingutsheni Hospital during a period of 3 months, were allocated alternately to treatment with either clothiapine or chlorpromazine. Six patients were excluded from the trial because of an incorrect diagnosis and 34, 17 in each group, completed the trial. The 2 groups were comparable for both severity and symptoms of their illnesses. Degrees of regression of psychotic symptoms as assessed by the Brief Psychiatric Rating Scale, were comparable for the 2 groups. Adverse effects were not troublesome with clothiapine and there was no evidence of disturbed liver function, but haemoglobin values and white cell counts were sometimes decreased. EEG studies showed that clothiapine produced an increase in the slow activity but no paroxysmal acitvity. It was concluded that clothiapine is a valuable drug for the management of actue schizophrenia.
 ...
PMID:Clothiapine in the management of schizophrenia. 1 24

The glucose, lactate, and pyruvate levels, the lactate/pyruvate ratio and pH were studied in serum and CSF of patients with schizophrenia, reactive psychosis, symptomatic or circular psychosis under the effect of atropine coma, ES and pentetrazole convulsions, tranquilizer treatment and combined therapy. Convulsive therapy caused a disorder in cerebral carbohydrate metabolism while no similar changes were induced by atropine coma. Anaerobic carbohydrate metabolism was stimulated by combined therapy. This treatment had the best effect and the changes caused by it were slighter than in the case of convulsive therapy. The changes in EEG frequency corresponded to the biochemical changes.
 ...
PMID:Biological studies on the effects of some therapeutic procedures used in psychiatry. 1

There has been much controversy in the past surrounding the relationship between schizophrenia and epilepsy. One hypothesis has been that the two disorders are antagonistic. The evidence supporting the antagonism hypothesis is briefly reviewed. A new theory based on current knowledge of the relationship of dopamine to both disorders is postulated which may explain the relationship between the psychosis and epilepsy which occurs in a subgroup of schizophrenic patients. In the light of this hypothesis it is suggested that further clinical work be undertaken to clarify further the exact association between the two disorders.
 ...
PMID:The relationship between epilepsy and schizophrenia: a biochemical hypothesis. 1 65

The Collaborative Neuropsychological Study of Polydrug Users performed extensive neuropsychological assessments on 15 polydrug users 3 weeks after their enrollment in each of eight polydrug demonstration programs. Fifty-six (37%) of these subjects exhibited neuropsychological deficit. This deficit was partially related to increasing age, poor education and premorbid medical risk factors. The deficit was also associated with extensive and intensive use of two classes of drugs: sedatives (sleeping pills and minor tranquilizers) and opiates (heroin and other narcotic drugs). Seventeen (26%) of a comparison group of 66 psychiatric in-patients and day patients also demonstrated age- and education-correlated neuropsychological deficit. For these patients impairment was also related to lifetime experience with antipsychotic drugs and (perhaps) with clinical diagnosis of schizophrenia. Although both polydrug users and psychiatric patients revealed serious psychopathology as measured by the MMPI, the pattern of the neuropsychological test findings suggested that psychopathology alone did not account for impairment. The 3 month follow-up which is in progress should delineate further the time course and enduring features of neuropsychological deficit among polydrug users, and may establish more clearly the relationship of sedative and opiate use to such impairment. Changes in psychopathological status of both polydrug users and psychiatric patients should also help to clarify the influence of this variable on neuropsychological findings.
 ...
PMID:Neuropsychological deficit in polydrug users. A preliminary report of the findings of the collaborative neuropsychological study of polydrug users. 1 18

It was hypothesized that primary process expression on Gottschalk's Five Minute Verbalization Task (FMV) would be more representative of clinical status in schizophrenia than primary process expression on the Rorschach. Ss were 21 males and 15 females, ages 19-41 years, newly admitted to the hospital and treated with phenothiazines. The FMV was administered at predrug, five weeks, and 13 weeks, and the Rorschach at predrug and five weeks. Primary process scoring was according to the Holt system. Clinical improvement was measured by the Lorr IMPS and the Burdock Ward Behavior Scale. Over time, Ss produced less primary process on the FMV (p less than .001), while on the Rorschach scores did not change significantly. The scores on the FMV but not on the Rorschach paralleled some measures of clinical improvement (p less than .05). In a factor analysis, scores on the FMV and Rorschach were related to specific but different symptoms. It was concluded that the FMV was more effective in determining clinical improvement, while the Rorschach was perhaps more valuable in assessing the nature of the primary process thinking.
 ...
PMID:Changes in primary process expression in hospitalized schizophrenics treated with phenothiazines: two projective tasks compared. 1 82

1 Thioridazine can be specifically, simply, and reliably measured in plasma and urine by gas chromatography using hexane extraction and prochlorperazine as internal standard; fluorimetry is non-specific. 2 The method can also measure thioridazine ring sulphoxide, and mesoridazine-plus-sulphoridazine (M/S). 3 After single doses plasma sometimes shows M/S in addition to thioridazine itself; it always does so on continued treatment. There is great individual variation in both components, and evidence of changes in metabolism during the early weeks. 4 Urinary excretion may be influenced by pH, but between pH 6.0-7.0 about 1% of the daily dose appears in 24 h urine as the following: free thioridazine in microng quantities, M/S and ring sulphoxide each in mg amounts. 5 Patients attain steady state conditions, although plasma levels rise considerably after each dose and settle again in about 10 h. After chronic treatment is stopped to half-life is at about 30 h. 6 Plasma levels cannot be related to therapeutic response when this is slow, as in schizophrenia, but interpretations are complicated by the production of clinically active metabolites, and by plasma protein binding.
 ...
PMID:Measurement of thioridazine in blood and urine. 1 33

According to the dopamine (DA) hypothesis of schizophrenia, there is a functional excess of dopaminergic activity within unspecified areas of the brain in schizophrenic patients. As a clinical test of this hypothesis, we administered metyrosine for three weeks to symptomatic chronic male schizophrenic patients who were maintained on suboptimal doses of neuroleptic agents. Metyrosine inhibits tyrosine hydroxylase, the rate-limiting enzymatic step in the synthesis of DA. No clinical improvement was observed, using the National Institute of Mental Health Inpatient Behavioral Rating Scale or the Brief Psychiatric Rating Scale. Central inhibition of DA synthesis by metyrosine was suggested, however, by (1) the development of extrapyramidal side effects and (2) a significant increase in plasma prolactin concentrations. Plasma chlorpromazine concentrations remained unchanged during metyrosine treatment. There was, nevertheless, a significant improvement on the scores of the Wechsler Adult Intelligence Scale Comprehension subtest, which measures judgment and common sense. This finding suggests that DA may be involved in the regulation of subtle psychological processes. The results are discussed in light of the DA hypothesis of schizophrenia and previous reports suggesting that metyrosine potentiates the antipsychotic effect of neuroleptics in schizophrenia.
 ...
PMID:Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine. 1 74

A hypothesis is put forward in regards to what is called "chronic schizophrenia" that those observations which suggest a continuing disease process may turn out not to be intrinsic facets of schizophrenia as a neurochemical instability but rather neurotic reactions to the acute schizophrenic process. The hypothesis goes on to suggest that this reaction to the acute psychosis is such as to constitute a traumatic neurosis and that while controlling the psychosis with an "umbrella" of major tranquilizers, it is possible to resolve this neurosis. Resolution of the neurosis requires a particular approach to therapy. This is a hypothesis which is very much open to experimental examination and one which may, if proven, markedly affect the postpsychosis management of schizophrenia.
 ...
PMID:The trauma of being psychotic: a neglected element in the management of chronic schizophrenia? 1 48

An open clinical study was conducted with carpipramine in 100 hospitalized subjects presenting various mental disorders. The therapeutic results on symptoms were assessed both as a whole and with the help of a rating scale. Doses varied from 50 to 400 mg per day. Carpipramine seems to be particularly efficient on schizophrenias, 66 cases of which were tested. The best results were observed in hebephrenic forms and depressive syndroms during the illness; in these indications, carpipramine exerts a clear psychomotor stimulating activity which is useful in decreasing indifference, apathy and ideomotor slowness. Schizophrenias with paranoid delusions or depersonalization anxiety tend to be somehow aggravated. Carpipramine does not seem to be a true antidepressant despite its desinhibitory properties. The compound proves useful in deficits of the psychomotor tone such as those occuring in psychasthenia or the deficit syndrom which follows withdrawal from opiates. Clinical and biological tolerances seem to be excellent and extrapyramidal side effects are exceptional. Carpipramine may be considered as a strongly desinhibitory neuroleptic agent which bears some resemblance to antidepressants because of its psychoanaleptic effect. The authors raise the question of possible antipsychotic properties in higher doses in relation to pharmacological data and a bipolar, antipsychotic and predominantly desinhibitory, therapeutic action.
 ...
PMID:[A new psychotropic drug: carpipramine, intermediate compound between 2 therapeutic classes]. 1 31

A macro- and microscopic study of genital glands was conducted in 33 cases of schizophrenia (14 females and 19 males). A practically normal histological picture of the ovary and testis was found in 12 cases, different degrees of involutional (atrophic) changes in 19 and tumours in 2 cases. The degree of expressed histological changes correlated with age and duration of the disease. Correlation between the histology of genital glands on the one hand and the duration and intensity of psychopharmacological treatment on the other one (mainly by neuroleptics) were not found.
 ...
PMID:[Sex gland morphology of schizophrenic patients during treatment with psychotropic drugs]. 1 6


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>